• Events
    • Future Meetings
    • Digital Events
    • EURETINA 2022 Hamburg
      • Browse Programme
      • Registration Information
      • Hotel Bookings
    • EURETINA 2021 Virtual
      • 2021 Virtual Sessions On-Demand (Members Only)
      • Programme
      • Satellite Symposia
      • Sponsors
  • Free Resources
    • Webinars
    • Podcasts
    • 2021 Virtual Session Abstracts
    • EURETINA Guidelines
    • EURETINA Brief
    • IME ePlatform
  • Membership
  • About
    • EURETINA Board
    • Subspecialty Sections
    • Bye-laws
  • Opportunities
    • Mentorship Programme 2022/23
    • RMCR grant programme
    • Observership Grant Programme
    • Women in Retina
    • YOURS
    • CME Credits
  • Member Login
Menu
  • Events
    • Future Meetings
    • Digital Events
    • EURETINA 2022 Hamburg
      • Browse Programme
      • Registration Information
      • Hotel Bookings
    • EURETINA 2021 Virtual
      • 2021 Virtual Sessions On-Demand (Members Only)
      • Programme
      • Satellite Symposia
      • Sponsors
  • Free Resources
    • Webinars
    • Podcasts
    • 2021 Virtual Session Abstracts
    • EURETINA Guidelines
    • EURETINA Brief
    • IME ePlatform
  • Membership
  • About
    • EURETINA Board
    • Subspecialty Sections
    • Bye-laws
  • Opportunities
    • Mentorship Programme 2022/23
    • RMCR grant programme
    • Observership Grant Programme
    • Women in Retina
    • YOURS
    • CME Credits
  • Member Login
  • February 11, 2020
  • Author: EURETINA Brief

Applied Genetic Technologies Corporation (Nasdaq: AGTC) reports interim Phase 1/2 achromatopsia study data

Applied Genetic Technologies Corporation (Nasdaq: AGTC), a gene therapy company in Florida, has reported encouraging interim six-month data from dose-escalation cohorts of a Phase 1/2 trial in patients with achromatopsia.  According to the sponsor, interim results demonstrated “encouraging signs of biologic activity and a favorable safety profile”.  The study is listed at the US clinical trials database, entitled “Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGB3 Achromatopsia” and has the identifier of NCT02599922 at clinical trials.gov, also referred to “ACHMB3 Achromatopsia Phase 1/2 Clinical Trial”, listed at the AGCT company.

 

Achromatopsia (ACHM) is a rare disorder with an estimated prevalence of 1:30,000, characterized by reduced visual acuity, pendular nystagmus, photophobia, eccentric fixation and reduced or complete lack of colour discrimination.  Best visual acuity varies with severity of the disease; it is 20/200 or less in complete achromatopsia and may be as high as 20/80 in incomplete achromatopsia. The disorder is an inherited condition caused by mutations in one of several genes, with the two most common being mutations in either the CNGB3 or CNGA3 genes.  According to the company, there is no specific treatment for ACHM, “although deep red tinted glasses or contact lenses can reduce symptoms of light sensitivity and daytime blindness”.  Two separate AAV gene therapy product candidates for the two most prevalent forms of ACHM are caused by either a genetic mutation in the CNGB3 or CNGA3 genes. Two genetic mutations account for up to 75% of the ACHM patient population.  AGTC’s ACHM programs are designed to provide a functional copy of the cyclic nucleotide gated (CNG) ion channel B3 or A3 subunit genes to cone photoreceptors.

 

To date, the interim study reports that the experimental treatment is generally safe and well-tolerated, and describes “preliminary signs of biologic activity”.  Dosing two higher groups of adult patients and three groups of paediatric patients are included across both trials – 17 patients in B3 patients and 15 patients in A3.  At present, more than half of the patients already are enrolled with 3-6 month data available in second half of 2020.  Commenting on the milestone, Sue Washer, CEO of AGTC has stated that, “we are pleased that both of our achromatopsia clinical candidates are demonstrating preliminary signs of biologic activity for patients who have no current treatment options for a disease that significantly compromises their vision and quality of life. We are further encouraged by many patients’ real-world positive anecdotes. We are continuing dose escalation in order to determine the highest safe dose with the potential to provide maximal benefit.”

PrevPrevious
NextNext

You might also like

EURETINA Hamburg 2022 Keynote Speakers

Read More

EURETINA Educational Webinar: Diabetes and Vascular Diseases (23 Jun, 2022)

Read More

Apellis International: The Future of Geographic Atrophy: advancing diagnosis, treatment and management

Read More

Meet the Keynote Speakers

Keynote Speaker - Sobha Sivaprasad
Euretina Lecture with Sobha Sivaprasad
Opthalmologica Lecture with Enrico Borrelli
Ophthalmologica Lecture with Enrico Borrelli
Gisbert Richard Lecture with Catherine Creuzot-Garcher
Gisbert Richard Lecture with Catherine Creuzot-Garcher
Kreissig Award Lecture with Hiroko Terasaki
Kreissig Award Lecture with Hiroko Terasaki

Secretariat Address
European Society of Retina Specialists
Ground Floor, The Apex Building 
Blackthorn Road
Sandyford Business Park
Co Dublin, D18 H6K2

Phone:+353 1 2100092
Email: [email protected]

EURETINA 2022 Hamburg

Opportunities

Memberships

Forum

About

Privacy Policy

Newsletter Sign up

By clicking 'Subscribe', you agree to the terms of our Privacy Policy. 
 
 

Follow us

© EURETINA 2021 All rights reserved
  • Events
    • Future Meetings
    • Digital Events
    • EURETINA 2022 Hamburg
      • Browse Programme
      • Registration Information
      • Hotel Bookings
    • EURETINA 2021 Virtual
      • 2021 Virtual Sessions On-Demand (Members Only)
      • Programme
      • Satellite Symposia
      • Sponsors
  • Free Resources
    • Webinars
    • Podcasts
    • 2021 Virtual Session Abstracts
    • EURETINA Guidelines
    • EURETINA Brief
    • IME ePlatform
  • Membership
  • About
    • EURETINA Board
    • Subspecialty Sections
    • Bye-laws
  • Opportunities
    • Mentorship Programme 2022/23
    • RMCR grant programme
    • Observership Grant Programme
    • Women in Retina
    • YOURS
    • CME Credits
  • Member Login